Synexus hopes to have the new sites completed by March 2009. Synexus, which acquired the clinical trial business CRC in 2006, said that it has found South Africa to be an excellent place to undertake clinical trials across a wide variety of therapy areas and phases.
The Pretoria site is expanding into the adjoining building which will be converted into a full 562sqm clinical trials unit for outpatients. The existing building contains a 36-bed Phase I and IIa trial facility. Siting of the clinical trial clinics in Mamelodi and Soshanguwe are presently being negotiated with the local authorities, said Synexus.
The Synexus-owned clinical trial units as well as affiliated sites within South Africa are involved in a variety of therapeutic areas including paediatric vaccines, osteoporosis, women’s health, post-operative pain and across Phases II and III.
Michael Fort, CEO of Synexus, said: “South Africa has proven to be one of our most successful sites both in terms of achieving high numbers of patients and also in the quality of the trials carried out. We will continue to expand our presence in South Africa.”